Northwestern University scientists say a homegrown experimental drug candidate is hitting a particularly nasty form of Alzheimer’s biology early and hard - at least in mice.
The small molecule, known as NU‑9, sharply reduced a newly identified, highly toxic subtype of amyloid‑beta oligomers and blocked several early brain changes when given before symptoms appeared in mouse models, according to the team. Led by chemist Richard Silverman and neurobiologists William Klein and Daniel Kranz, the researchers report lower markers of inflammation, reduced levels of abnormal TDP‑43 that show up early in Alzheimer’s models, and improved measures they associate with neuronal health. The findings raise the possibility of a preventive strategy, but all of the work so far is in preclinical models and NU‑9 has not been tested for Alzheimer’s in people.
Study details and where it appeared
The new results are described in a paper in Alzheimer’s & Dementia. Northwestern’s Feinberg School of Medicine reports that the group zeroed in on a glia‑associated oligomer subtype that binds to astrocytes and triggers early reactive astrogliosis. In a pre‑symptomatic mouse experiment, the team dosed animals daily for 60 days and saw what they call dramatic reductions in the ACU193‑positive oligomer, along with less neuroinflammation and drops in an abnormal form of TDP‑43. Those brain‑wide shifts point to a potential early intervention window before memory loss appears, according to the Feinberg School of Medicine.
A target antibody and a small‑molecule partner
The subtype the team labels ACU193+ is defined by its detection with the oligomer‑selective antibody ACU193, an approach other labs are already testing in human trials, according to Frontiers in Neuroscience. Klein and Kranz also co‑founded Acumen Pharmaceuticals, which is developing a monoclonal antibody aimed at the same oligomer class, as reported by Crain’s Chicago Business. The researchers frame that combination - an antibody that binds toxic oligomers outside cells and a small molecule that helps clear them inside cells - as the basis for an early, biomarker‑driven intervention strategy.
Where NU‑9 came from and the path toward humans
NU‑9 traces back about 15 years to Silverman’s chemistry lab, part of a long search for small molecules that could head off toxic protein aggregation. The compound is now being developed commercially by Akava Therapeutics under the name AKV9. Akava and trade outlets have noted that the FDA cleared an IND in 2023 to begin first‑in‑human testing of AKV9 for ALS, based on a company press release summarized by BioSpace. Northwestern’s public materials on the work spell out that some investigators have financial ties to the startups involved, with those conflicts disclosed in media notices that accompany the research.
“There are a couple early diagnostic blood tests for Alzheimer’s disease in development,” Klein said in a Northwestern statement, adding that “the promise of better early diagnostics - combined with a drug that could stop the disease in its tracks - is the goal.” Silverman compared the idea to cholesterol prevention: if biomarkers flag elevated risk, taking a drug before symptoms show up could be similar to taking cholesterol‑lowering medicine to ward off a heart attack. Both comments come from the team’s statement released with the paper.
What’s next for NU‑9
The researchers say they are now moving into animal models of late‑onset Alzheimer’s and planning longer follow‑ups to see whether early NU‑9 treatment can head off later memory decline and neuronal loss, according to coverage from MedicalXpress. They also plan to dig deeper into the drug’s lysosome‑dependent mechanism, which appears to steer toxic proteins into cellular recycling pathways, to test whether that action consistently restores synaptic health across models. Those studies are intended to build the preclinical data package that companies and regulators would expect before considering human trials focused specifically on Alzheimer’s.
Caveats and regulatory reality
The team and outside observers note a familiar problem: many therapies that look strong in mouse models never pan out in people. NU‑9’s human track record so far comes from an ALS IND and early safety work, not from any Alzheimer’s efficacy studies. Akava’s IND for AKV9 is centered on ALS and emphasizes that establishing safety and appropriate dosing in humans is a separate challenge from proving a disease‑modifying effect in Alzheimer’s, as summarized by BioSpace. Turning a pre‑symptomatic, biomarker‑guided prevention concept into clinical reality would also require validated early diagnostics and large, lengthy trials that clearly demonstrate slower cognitive decline.
Why Chicago should watch
The project keeps Northwestern’s labs and Chicago’s biotech scene in the spotlight, with campus spinouts like Akava and Acumen trying to shepherd local discoveries toward the clinic. If NU‑9 or an Acumen antibody ultimately proves safe and effective in people, the payoff could be huge, although that scenario is still years away and entirely dependent on rigorous clinical testing. For now, the work adds a fresh clue about the earliest stages of Alzheimer’s biology and puts another Chicago‑linked drug candidate on the watch list.
